NEW YORK and LONDON, March 31, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
NEW YORK and LONDON, March 1, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that …
Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day
NEW YORK and LONDON, February 17, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
NEW YORK and LONDON, January 29, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the …
Akari Therapeutics to Participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day
NEW YORK and LONDON, January 27, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …
